United States - English - NLM (National Library of Medicine)

pharmaceutics international, inc. (pii) - bretylium tosylate (unii: 78zp3yr353) (bretylium - unii:rzr75eq2kj) - bretylium tosylate injection, usp is indicated in the prophylaxis and therapy of ventricular fibrillation. bretylium tosylate injection, usp is also indicated in the treatment of life-threatening ventricular arrhythmias, such as ventricular tachycardia that have failed to respond to adequate doses of a first-line antiarrhythmic agent, such as lidocaine. use of bretylium tosylate injection, usp should be limited to intensive care units, coronary care units or other facilities where equipment and personnel for constant monitoring of cardiac arrhythmias and blood pressure are available. following injection of bretylium tosylate there may be a delay of 20 minutes to 2 hours in the onset of antiarrhythmic action, although it appears to act within minutes in ventricular fibrillation. the delay in effect appears to be longer after intramuscular than after intravenous injection. there are no contraindications to use in treatment of ventricular fibrillation or life-threatening refractory ventricular arrhythmias, excep

United States - English - NLM (National Library of Medicine)

ani pharmaceuticals, inc. - bretylium tosylate (unii: 78zp3yr353) (bretylium - unii:rzr75eq2kj) - bretylium tosylate injection, usp is indicated in the prophylaxis and therapy of ventricular fibrillation. bretylium tosylate injection, usp is also indicated in the treatment of life-threatening ventricular arrhythmias, such as ventricular tachycardia that have failed to respond to adequate doses of a first-line antiarrhythmic agent, such as lidocaine. use of bretylium tosylate injection, usp should be limited to intensive care units, coronary care units or other facilities where equipment and personnel for constant monitoring of cardiac arrhythmias and blood pressure are available. following injection of bretylium tosylate there may be a delay of 20 minutes to 2 hours in the onset of antiarrhythmic action, although it appears to act within minutes in ventricular fibrillation. the delay in effect appears to be longer after intramuscular than after intravenous injection. there are no contraindications to use in treatment of ventricular fibrillation or life-threatening refractory ventricular arrhythmias, excep

Canada - English - Health Canada

sandoz canada incorporated - bretylium tosylate - solution - 50mg - bretylium tosylate 50mg - class iii antiarrythmics

Canada - English - Health Canada

abbott laboratories, limited - bretylium tosylate; dextrose - solution - 4mg; 50mg - bretylium tosylate 4mg; dextrose 50mg - class iii antiarrythmics

Canada - English - Health Canada

abbott laboratories, limited - bretylium tosylate; dextrose - solution - 2mg; 50mg - bretylium tosylate 2mg; dextrose 50mg - class iii antiarrythmics

Canada - English - Health Canada

abbott laboratories, limited - bretylium tosylate - solution - 50mg - bretylium tosylate 50mg - class iii antiarrythmics

New Zealand - English - Medsafe (Medicines Safety Authority)

abbott laboratories (nz) ltd - bretylium tosilate 50 mg/ml - solution for injection - 50 mg/ml - active: bretylium tosilate 50 mg/ml excipient: hydrochloric acid sodium hydroxide water for injection

Canada - English - Health Canada

glaxo wellcome inc. - bretylium tosylate - liquid - 50mg - bretylium tosylate 50mg - class iii antiarrythmics

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

celltech pharma europe ltd - bretylium tosilate - solution for injection - 50mg/1ml

New Zealand - English - Medsafe (Medicines Safety Authority)

boots healthcare new zealand limited - bretylium tosilate 50 mg/ml;   - solution for injection - 500mg/10ml - active: bretylium tosilate 50 mg/ml